After treatment, patients are followed up for up to 8 hours. At this point, the study procedures will be repeated. Or two, if the first gel reduces nausea by more than 1 point on the 0-10 scale, subjects will wait 4 hours to apply the next gel. If there is no effect in one hour from second drug, patients will stop the study and resume normal treatment for their nausea. One, if there is no effect after the first drug in one hour, then patients will receive the second drug. Subjects will be asked to rate and complete their nausea on the Memorial Symptom Assessment Scale (CMSAS). Subjects will rub 1 mL of the first drug, Drug A gel, between their wrists for 2 minutes.

It will be rubbed on the volar surface of the wrists by the subject, for 2 minutes as done in clinical practice, at time 0. Neither the patient nor the investigator will have knowledge of the actual content of Drug A or B, so the study will be double-blinded, and placebo controlled.ĭrug A: The dose of the drugs in the 1.0 mL dose will be 2 mg of lorazepam, 25 mg of diphenhydramine, and 2 mg of haloperidol in a pluronic lecithin organogel. The randomization list will be generated by the Study Biostatistician. OUTLINE: All individuals who are eligible are randomized to a sequence of treatments: either placebo-ABH or ABH-placebo. The primary outcome is the change in numeric rating scale in self-reported nausea on a 0-10 scale from baseline to 60 minutes of treatment.

Why Should I Register and Submit Results?.

Half life 2 abh